No profile data available.
Cardiff Oncology, Inc. (CRDF) is a healthcare company in the DNA testing equipment industry, based in San Diego, United States, with about 32 full-time employees.
It reported revenue of $593,000 for fiscal year 2025, down 13.2% from fiscal year 2024, and net income of -$45.88 million. Its market capitalization was $145.50 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Cardiff Oncology reported $593,000 in revenue for fiscal year 2025, down 13.2% from $683,000 in fiscal year 2024.
$145.50 million as of December 4, 2025.
Listed companies of a similar size in the same industry (DNA testing equipment) include Castle Biosciences, Inc. (CSTL), Myriad Genetics, Inc. (MYGN), Burning Rock Biotech Limited (BNR), Sera Prognostics, Inc. (SERA).